Literature DB >> 8480342

Thymectomy as treatment of autoimmune diseases other than myasthenia gravis.

V D'Andrea1, L Malinovsky, V Ambrogi, M Artico, L G Capuano, F Buccolini, E De Antoni.   

Abstract

This paper reviews the different series of thymectomies performed in patients with autoimmune diseases other than myasthenia gravis. It is possible that thymectomy can decrease the activity of T-helper lymphocytes or, alternatively, it may enhance the activity of T-suppressor lymphocytes, whose function is depressed in autoimmune diseases. Thymectomy was performed empirically for systemic lupus erythematosus and rheumatoid arthritis. The therapeutic benefits were questionable. Conflicting results were reported for thymectomy against autoimmune hemolytic anemia. Several trials were conducted to assess the therapeutic value of thymectomy in multiple sclerosis. Benefits were achieved only in relapsing-remitting but not in chronic-progressive multiple sclerosis. The effect of thymectomy in autoimmune diseases associated with myasthenia gravis were also reported. The authors conclude that thymectomy as treatment for autoimmune diseases other than myasthenia gravis is not elective therapeutic choice and it is acceptable only in selected cases.

Entities:  

Mesh:

Year:  1993        PMID: 8480342

Source DB:  PubMed          Journal:  Thymus        ISSN: 0165-6090


  2 in total

1.  Pure Red Cell Aplasia and Other Haematological Diseases Associated With Thymoma: A Case Series and Systematic Review.

Authors:  Chih-Chieh Yen; Wei-Li Huang; Sin-Syue Li; Ya-Ping Chen; Yau-Lin Tseng; Yi-Ting Yen; Chang-Yao Chu; Ya-Ting Hsu; Tsai-Yun Chen
Journal:  Front Med (Lausanne)       Date:  2021-12-13

2.  Immunological signature of patients with thymic epithelial tumors and Good syndrome.

Authors:  Anna Maria Malfitano; Vittoria D'Esposito; Pietro De Placido; Marianna Tortora; Margaret Ottaviano; Erica Pietroluongo; Rocco Morra; Brigitta Mucci; Fabiana Napolitano; Liliana Montella; Mario Giuliano; Sabino De Placido; Daniela Terracciano; Giovannella Palmieri; Pietro Formisano
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.